生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 12-22 16:00:00

5,900.420

-43.197

-0.73%

最高5,986.019	最低5,883.112	成交量1.41亿
今开5,942.502	昨收5,943.617	日振幅1.73%
总市值0.00	流通市值0.00	总股本0.00
成交额38.27亿	换手率--	流通股本0.00
市净率7.735965	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5900.42,"timestamp":1766390888436,"preClose":5943.6167,"halted":0,"volume":140622520,"delay":0,"changeRate":-0.007268,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-43.196777,"latestTime":"12-22 16:00:00","open":5942.5024,"high":5986.0186,"low":5883.112,"amount":3827408809,"amplitude":0.017314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1766367000000,1766376000000],[1766379600000,1766390400000]],"pbRate":7.735965,"peRate":-79.389631,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2593434692","title":"亚盛医药盘中异动 早盘股价大跌5.49%报27.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434692","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593434692?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:30","pubTimestamp":1766421039,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日00时30分，亚盛医药股票出现异动，股价急速跳水5.49%。截至发稿，该股报27.70美元/股，成交量3048股，换手率0.00%，振幅3.00%。亚盛医药股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，健永生技、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Pmgc Holdings Inc.、Psyence Biomedical Ltd.、Aditxt, Inc.较为活跃，换手率分别为141.64%、56.29%、30.64%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、健永生技、Apollomics Inc C/Wts 01/04/2028 ，振幅分别为343.55%、142.43%、103.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223003040953b84fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223003040953b84fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","ASPHF","BK1161","06855"],"gpt_icon":0},{"id":"2593043352","title":"思路迪医药股份(01244)：恩维达®胃癌和胃食管结合部癌适应症获孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043352","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593043352?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:12","pubTimestamp":1766412751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份(01244)发布公告，旗下商业化产品恩维达® (通用名：恩沃利单抗注射液，原研代号：KN035)针对胃癌和胃食管结合部癌适应症正式获得孤儿药资格认定，这是恩维达®继胆管癌和软组织肉瘤适应症后成功获批的第叁个孤儿药适应症。此次获批基于本公司开展的恩维达®晚期胃/食管胃结合部腺癌的II期临床研究展现出明确的抗肿瘤疗效，其联合FOLFOX方案的客观缓解率达60%，疾病控制率高达100%，且安全性与耐受性良好，无导致治疗终止或死亡的不良事件发生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01244"],"gpt_icon":0},{"id":"1168608302","title":"思路迪医药股份 - 中国Nmpa对胃癌及胃食管交界癌的治疗指征认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168608302","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168608302?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:11","pubTimestamp":1766412675,"startTime":"0","endTime":"0","summary":"思路迪医药股份 - 中国Nmpa对胃癌及胃食管交界癌的治疗指征认定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244","BK1161"],"gpt_icon":0},{"id":"2593808164","title":"派格生物医药-B(02565)完成发行合共513.6万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593808164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593808164?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:59","pubTimestamp":1766408368,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，配售协议的所有条件已获达成，配售已于2025年12月22日完成。根据配售协议的条款及条件，联席配售代理已以每股配售股份58.41港元的价格向不少于6名承配人配售合共513.6万股配售股份，相当于紧随配售完成后，经配发及发行配售股份扩大的H股的约1.81%及股份总数的约1.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","02565","399441","BK1161"],"gpt_icon":0},{"id":"1184306238","title":"和誉-B的Csf-1R抑制剂Pimicotinib获得中国NMPA批准，填补腱鞘巨细胞瘤的治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=1184306238","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184306238?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:31","pubTimestamp":1766403072,"startTime":"0","endTime":"0","summary":"和誉-B的Csf-1R抑制剂Pimicotinib获得中国NMPA批准，填补腱鞘巨细胞瘤的治疗空白","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","BK1161","LU2476274720.SGD","LU2778985437.USD","02256","LU2476274308.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2593148175","title":"沙利文毛化：中国创新药2026年迎升浪，加速国际化价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148175","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593148175?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:16","pubTimestamp":1766402190,"startTime":"0","endTime":"0","summary":"近一年来，中国药企在国际舞台上频频亮相，国际社会对中国制药业的发展关注度持续攀升。正如《经济学人》所指出的：中国创新药正处于全球化的临界点。从中国临床试验的参与度到对外授权许可的规模，中国药企在全球市场的占比均显著提升；过去一年，中国生物科技企业的股价涨幅远超美国同类企业，这一切无不表明，全球生物医药创新长达一个世纪的“西方主导”格局正悄然改变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598433738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598433738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2593481246","title":"董事会主席钱雪明增持创胜集团(06628)1万股 每股作价约2.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481246","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593481246?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:12","pubTimestamp":1766401939,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团(06628)1万股，每股作价2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06628","BK1161"],"gpt_icon":0},{"id":"2593481733","title":"非执行董事郭华清增持科济药业(02171)1.8万股 每股作价14.52港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481733","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593481733?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:06","pubTimestamp":1766401576,"startTime":"0","endTime":"0","summary":"12月18日，非执行董事郭华清增持科济药业(02171)1.8万股，每股作价14.52港元，总金额约为26.14万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251222/20251222190654_25742.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251222/20251222190654_25742.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"非执行董事郭华清增持科济药业(02171)1.8万股 每股作价14.52港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1587","BK1574","BK1161","BK1585","02171"],"gpt_icon":0},{"id":"2593894344","title":"启迪药业最新公告：证券简称拟变更为“古汉医药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593894344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593894344?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:49","pubTimestamp":1766400581,"startTime":"0","endTime":"0","summary":"启迪药业(000590.SZ)公告称，公司第十届董事会临时会议于2025年12月22日召开，会议审议通过《关于变更公司证券简称的议案》。公司证券简称将由“启迪药业”变更为“古汉医药”，并向深圳证券交易所提交证券简称变更申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","000590","BK0239","BK1515","159938","BK1161","BK0122","161027"],"gpt_icon":0},{"id":"2593485449","title":"歌礼制药-B(01672)12月22日斥资249.37万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485449?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:54","pubTimestamp":1766397251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月22日，该公司斥资249.37万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","01477","BK1191","BK1161","01672"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》，涉及药品：“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂，拟用于前列腺癌的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","06978","BK1574","IND","002653","BK0033","BK0077","BK1161","BK0239","159992"],"gpt_icon":0},{"id":"2593043083","title":"罕见病治疗药物贝捷迈在华获批 国内首个获批用于TGCT治疗一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043083","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593043083?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:28","pubTimestamp":1766395680,"startTime":"0","endTime":"0","summary":"贝捷迈是一款由和誉医药研发的集落刺激因子-1受体抑制剂，也是国内首个获批用于TGCT治疗的一类创新药。“随着贝捷迈在全球的首个注册获批，我们正持续践行改善罕见肿瘤患者生活的承诺。”蔻德罕见病中心创始人、主任，瑞鸥公益基金会创始人、秘书长黄如方表示，随着贝捷迈在中国获批，这一类系统性治疗方案能够有效控制肿瘤进展、缓解症状，也让患者看到了希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222173226a469d45d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222173226a469d45d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","06978","LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","BK1574","LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2593483499","title":"荣昌生物拟回购 金额2000万元至4000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483499","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483499?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:21","pubTimestamp":1766395284,"startTime":"0","endTime":"0","summary":"12月22日，荣昌生物（688331/09995）发布公告，计划以集中竞价交易方式回购股份，回购金额不低于2000万元且不超过4000万元，回购价格上限为95元/股，回购股份将用于员工持股计划或股权激励，回购期限为自董事会审议通过之日起12个月内。2025年前三季度，荣昌生物实现收入17.20亿元，归母净利润-5.51亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598357980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","BK0239","LU1969619763.USD","LU2488822045.USD","LU2148510915.USD","688331","BK1574","BK1161","LU1064130708.USD","BK1583","LU2328871848.SGD","09995"],"gpt_icon":0},{"id":"2593483841","title":"昊海生物科技(06826)12月22日斥资43.49万港元回购1.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483841","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483841?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:11","pubTimestamp":1766394668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2025年12月22日斥资43.49万港元回购1.7万股股份，每股回购价格为25.54-25.6港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"gpt_icon":0},{"id":"2593880584","title":"圣诺医药-B(02257)完成试验药物STP707的I期试验并已向FDA正式提交临床研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2593880584","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593880584?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:06","pubTimestamp":1766394393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B 发布公告，公司全资附属公司Sirnaomics, Inc.已完成试验药物STP707的I期试验，并已向美国食品药品监督管理局正式提交临床研究报告。STP707在该等患者中展示出确切的临床活性，部分患者疾病实现稳定，在治疗选择有限且经过多线既往治疗的群体中延缓了疾病进展。该等患者透过静脉给药方式接受了不同剂量的STP707。公司相信，完成I期试验并向FDA提交临床研究报告乃STP707的一个关键里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02257"],"gpt_icon":0},{"id":"2593883554","title":"嘉和生物-B(06998)拟将法定股本增至6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593883554","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593883554?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:34","pubTimestamp":1766392447,"startTime":"0","endTime":"0","summary":"智通财经APP讯，嘉和生物-B 公布，由于股东已于股东特别大会上以投票表决方式通过批准建议更改公司名称的第6 项决议案，故于本公告日期，建议更改公司名称的条件已获达成。由于股东已于股东特别大会上以投票表决方式通过批准建议增加法定股本的第3 项决议案，公司法定股本已透过增设20亿股每股面值0.00002美元的股份，由2万美元增加至6万美元，该等股份在所有方面与公司现有股份享有同等地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06998","BK1574","BK1161"],"gpt_icon":0},{"id":"2593610044","title":"和誉-B(02256)：和誉医药CSF-1R抑制剂贝捷迈®获中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593610044","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593610044?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:32","pubTimestamp":1766392338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，2025年12月22日，公司的附属公司上海和誉生物医药科技有限公司(“和誉医药”)宣布，中国国家药品监督管理局(“NMPA”)批准贝捷迈®(盐酸匹米替尼胶囊)，适用于手术切除可能会导致功能受限或出现较严重并发症的症状性腱鞘巨细胞瘤(“TGCT”)成年患者。获批后，默克将尽快推动该产品惠及中国TGCT患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CSF","IE00B5MMRT66.SGD","LU2476274308.USD","LU2476274720.SGD","IE00B543WZ88.USD","BK1515","BK1161","09939","BK1574","IE00BPRC5H50.USD","LU2488822045.USD","02256","LU2778985437.USD","159938"],"gpt_icon":0},{"id":"2593434880","title":"每日卖空追踪 | 再鼎医药 12月22日卖空量成交99.05万股，卖空比例为9.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593434880?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392241,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间12月22日，涨0.51%，卖空量成交99.05万股，较上一交易日减少72.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163704a4699847&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163704a4699847&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","BK1588","LU2488822045.USD"],"gpt_icon":0},{"id":"2593434618","title":"每日卖空追踪 | 亚盛医药-B 12月22日卖空量成交1.47万股，卖空比例为0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593434618?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392238,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间12月22日，跌3.11%，卖空量成交1.47万股，较上一交易日减少93.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163647a46997f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163647a46997f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2593436686","title":"每日卖空追踪 | 昊海生物科技 12月22日卖空量成交7000股，卖空比例为7.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593436686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593436686?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392237,"startTime":"0","endTime":"0","summary":"昊海生物科技北京时间12月22日，跌0.62%，卖空量成交7000股，较上一交易日增加250%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163721a46998a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163721a46998a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06826","BK1593"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}